|
|
||||||||
1 From the Department of Ophthalmology, Royal Victoria Infirmary, Newcastle-upon-Tyne, United Kingdom; and the 2 Division of Ophthalmology, School of Medical Sciences, Bristol, United Kingdom.
| Abstract |
|---|
|
|
|---|
METHODS. LEW (RT1l) or PVG (RT1c) strain corneas were transplanted to PVG strain recipients and examined by slit lamp for clinical signs of rejection. Recipients were killed, and corneal epithelial sheets were removed and examined by adenosine diphosphatase (ADPase) staining for Langerhans cells (LC) and by immunohistology for leukocytes and adhesion molecules (T cells, macrophages, granulocytes, major histocompatibility complex [MHC] class II, CD2 and CD54 intercellular adhesion molecule [ICAM]-1) at a range of time points before, during, and after rejection, depending on the cell type sought. Normal and contralateral eyes were examined for ADPase+ and MHC class II+ cells.
RESULTS. Clinical rejection, as defined by stromal opacity, occurred between days 10 and 15 after transplantation. In 94% of allografts, a curved clinical epithelial rejection line was observed in which ADPase+/MHC class II+, CD4+, or CD8+ T cells were identified. There were significantly more infiltrating cells of all types in epithelia of allografts than in those of isografts. The most numerous cells were CD4+ and CD8+ T cells, suggesting preferential migration of these cells into the epithelium from underlying layers. Expression of MHC class II and ICAM-1 was induced on epithelial cells.
CONCLUSIONS. Epithelial rejection in rats is clinically similar to that in humans and occurs simultaneously with stromal infiltration. It may be mediated by T cells rather than macrophages. In isolation, its recognition in humans may be a useful indication that the patient is at high risk of endothelial rejection.
| Introduction |
|---|
|
|
|---|
Alldredge and Krachmer1 identified epithelial rejection in 10% of 156 grafts examined for at least 1 year, which represents 34% of those showing signs of rejection, compared with 72% showing endothelial rejection. One possible explanation for the observed lower incidence of epithelial rejection is that donor epithelium is rapidly replaced after transplantation by host tissue and is therefore absent by the time a donor-specific immune response has developed. However, human epithelial rejection can occur at least a year after transplantation1 and in a careful experimental study in rabbits, Khodadoust and Silverstein2 observed that epithelium is "neither sloughed off rapidly in the immediate post-operative period, nor is it even slowly replaced by recipient epithelium in the technically successful corneal transplant." Epithelial rejection, characterized by a rejection line beginning at the graft margin, was observed 6 months after transplantation and in vascularized corneal allografts, it occurred "in almost every instance." Khodadoust and Silverstein3 further showed that grafts of the epithelial layer alone could rapidly sensitize the host, with rejection occurring as early as 2 weeks after transplantation, although because of its mode of preparation, the transplanted tissue would almost certainly have contained many more donor type Langerhans cells (LCs) than the epithelium of a normal donor. In pigmented rats, we also occasionally noticed an epithelial rejection line. The purpose of this study was therefore to establish accurately the incidence of clinical epithelial rejection in rats and to correlate it with clinical signs of stromal rejection and with the profile of cells infiltrating the epithelial layer.
| Materials and Methods |
|---|
|
|
|---|
Corneal Transplantation and Clinical Evaluation
Transplantations were performed as previously
described.4
Briefly, the donor eye was removed, and the
central cornea was cut with a 3.5-mm trephine. Separation of the button
was completed with curved scissors. A 3.0-mm button was removed from
the recipient by a similar procedure and replaced by the donor button,
which was sutured in place with 12 interrupted 11-0 nylon sutures.
Atropine and chloramphenicol ointments were applied to the eye after
the operation. The sutures ends were cut as short as possible, and
grafts were examined daily until day 15 and then twice weekly
thereafter. An epithelial rejection line was sought, and corneas were
scored centrally for opacity (scale of 14), edema (14), and
vascularization (15). Graft rejection was defined as the day on which
donor corneal opacity became moderate or severe (a score of at least
3), which was greater than that seen in isografts at any time.
Removal of Epithelial Sheets
Rats were killed by intraperitoneal injection of pentobarbitone
sodium. Transplanted eyes were enucleated and incubated at 37°C in
5.0 mL prewarmed 2% EDTA for 3 to 4 hours. Under a binocular
dissecting microscope, cornealconjunctival epithelium was removed as
a whole sheet with forceps. Footpad epidermis was similarly removed for
use as positive control tissue.
Adenosine Diphosphatase Staining
Epithelial sheets were stained for ADPase activity by the
technique of MacKenzie and Squier5
with the modification
of Chaker et al.6
Briefly, specimens were first washed in
0.9% saline, fixed in cacodylate (40%) and formaldehyde (10%) for 1
hour at 4°C, washed in three changes of 0.2 M rinsing buffer
(Trismal; Sigma Chemical Co., Poole, UK), and left overnight in rinsing
buffer at 4°C. Subsequently, they were incubated in freshly prepared
prewarmed adenosine diphosphate (ADP; Sigma)-lead nitrate solution at
36°C for 70 minutes and washed twice in rinsing buffer. The color was
developed in 10% ammonium sulfide solution on glass slides for 20
minutes. The sheets were washed twice in distilled water and mounted
flat, basal layer upward, in Apathys medium (BDH Ltd., Poole, UK) and
sealed with clear nail polish. Positive control tissue consisted of
sheets of footpad epithelium.
Immunoperoxidase Staining
Epithelial sheets were washed twice in PBS and fixed in acetone
for 5 minutes. Endogenous peroxidase activity was blocked using 0.1%
hydrogen peroxide in 50% PBS and methanol, followed by 1.5% normal
horse serum. Sheets were then incubated with a specific monoclonal
antibody (major histocompatibility complex [MHC] class II [OX6]],
CD4 [W3/25], CD8
[OX8], CD2 [OX34], macrophage [ED2],
granulocyte [HIS48], CD54/ICAM-1 [1A29]) or a negative control IgG1
antibody (human complement factor 1 [OX21]) overnight at
4oC. All antibodies were IgG1 except HIS48, which
was IgM and OX34, which was IgG2a. Positive control lymph node sections
or footpad epithelium (for MHC class II only) were included in every
staining run for each antibody. Control experiments were also included
in which the primary antibody was omitted. Primary antibody was
followed by biotinylated horse anti-mouse IgG (preadsorbed with rat
serum; Vector Laboratories, Peterborough, UK) and ABC complex (Vector
Laboratories). Color was developed using diaminobenzidine (DAB; Sigma)
with 0.01% hydrogen peroxide, or, for MHC class II expression,
4-chloro-1-naphtol (Sigma). All antibodies were obtained from SeraLab
(Sussex, UK), except ED2 (SeroTec, Oxford, UK) and HIS 48 (PharMingen,
San Diego, CA). Specimens were washed in PBS in 25 multiwell plates
after incubation with each reagent and mounted as for ADPase staining
on glass slides.
Experimental Protocol
In pilot clinical experiments, rejection was under way within 15
days. Sutures were therefore left in place throughout, because of the
potential to cause further inflammation by their removal when rejection
was imminent. In a further series of experiments, epithelial sheets
were removed and stained on day 10 (just before rejection) and day 15
(during rejection) and at additional time points, depending on cell
type, as follows: ADPase+ cells on days 2, 6, 30,
and 100, in that these should be involved in early T-cell activation
and may persist for longer than effector cells;
CD4+ and CD8+ T cells on
days 6, 8, and 30, to determine whether CD4+
cells infiltrates earlier or persists longer than
CD8+ cells; and MHC class II and macrophages on
day 30, to determine whether dendritic cells (DCs) express class II and
whether antigen-presenting cells (APCs) persist as rejection resolves.
Granulocytes, CD2, and ICAM-1 were sought only on days 10 and 15. For
each cell surface marker, four to six sheets were examined at each time
point. Sheets from contralateral eyes and eyes from untreated animals
were stained only for ADPase and MHC class II. Slides were masked and
coded by a second operator. A microscope (x250 magnification; Leica,
Cambridge, UK) with an eyepiece graticule engraved with a squared grid
measuring an area of 0.4 mm x 0.4 mm was used to count stained cells
in two areas in the recipient (approximately midway between the limbus
and grafthost junction) and three in the donor (Fig. 1)
, from which mean values for recipient and donor were calculated. An
identifiable rejection line was not present in the areas counted. Only
MHC class II+ cells of dendritic morphology were
counted, and only round CD4+ and
CD8+ cells were counted. Other cell types were
counted irrespective of shape. Mean counts for donor and recipient were
calculated. Observations of the rejection line were made, but cells in
the line were not counted. ICAM-1 expression was measured by image
analysis of gray levels by computer (Quantimet 500+ software; Leica).
|
| Results |
|---|
|
|
|---|
|
|
Quantification of Cells
ADPase+ and MHC Class II+ Cells.
ADPase+ cells were typically of dendritic
morphology (Fig. 4A
). In epithelia from untreated rats and those contralateral to
transplants, these were found only in a dense collar at the limbus, and
the numbers remained unchanged after transplantation (data not shown).
However, by day 2 such cells were already present in donor tissue of
transplanted corneas (Fig. 5)
. They continued to increase in number in allografts until day 15
(Figs. 4A
5)
, which correlated strongly with the onset of clinical
rejection, whereas those in isografts remained constant (Figs. 4B
5)
.
The overall difference in number between allografts and isografts was
significant (P < 0.0001 in both host and donor
tissue). The change in cell numbers over time was also significantly
different in allografts compared with isografts (P <
0.001 for both host and donor tissue), reflecting increased numbers of
cells in allografts between days 10 and 30 (P < 0.0001
in the donor) but not in isografts (P = 0.3 in the
donor). The mean numbers on day 15 in allograft host and donor tissue
were 148 (95% CI 75244; n = 6) and 46 (95% CI, 1886;
n = 6) cells/mm2, respectively.
Despite the increasing number of cells in the donor of allografts,
there were consistently more ADPase+ cells in the
host than in the donor, until day 30 (Fig. 5)
, by which time the number
of cells in all parts of the epithelium was decreasing, as was the
severity of clinical opacity.
|
|
|
|
T Cells.
By day 6 after transplantation, the earliest time point investigated,
CD4+ and CD8
+ cells were
scattered throughout in the donor epithelium of allografts (Fig. 7)
and
isografts. The numbers increased in allografts until day 15, when both
subsets were more concentrated in a curved line (Figs. 4C
4D)
interpreted as the epithelial rejection line observed during slit lamp
microscopy. Overall, there were significantly more
CD4+ and CD8+ T cells in
the donor allografts than in isografts (P < 0.0001 in
both cases, corresponding to a mean count of 142 (95% CI 77226,
n = 6) CD4+ and 167 (95% CI 58332,
n = 5) CD8+
cells/mm2 in the allograft donor cornea on day 15
(Fig. 6)
. T cells of both subsets were more numerous than macrophages,
DCs, or granulocytes. The pattern of infiltration was consistent with
overall movement in one direction from recipient to donor, in that in
allografts they were more numerous in recipients on day 6, but were
three- to sixfold more numerous in the donor cornea on day 15 (Fig. 7)
.
The number of cells changed significantly with time in allografts
compared with isografts (P < 0.0001 and
P = 0.001 for CD4+ and
CD8+ cells, respectively), because numbers in the
donor allografts increased to a peak on day 15 (P <
0.0001 for CD4+ and P = 0.004
CD8+ cells), whereas those in isografts remained
at a constant low level (P > 0.05 and
P = 0.2 for CD4+ and
CD8+ cells, respectively). Many small round
cells, presumed to be T cells, expressed CD2 (Fig. 4E)
.
MHC Class II and ICAM-1 Expression on Epithelial Cells
Neither MHC class II nor ICAM-1 was detected on the epithelium of
normal corneas and MHC class II was not detected on isografts. However,
in the donor allografts, patchy expression of MHC class II was
observed, delineating the epithelial cell membrane (Fig. 4F) . ICAM-1
was expressed de novo in both allografts and isografts, but by analysis
of gray levels, expression was significantly greater on allografts
(P = 0.02). ICAM-1 was more evenly distributed and
homogeneous on epithelial cells than class II expression. ICAM-1 was
also expressed on infiltrating cells, including in the rejection line.
| Discussion |
|---|
|
|
|---|
In allografts the predominant infiltrating cells throughout the donor epithelium were T cells. These findings are consistent with the electron microscopic study of Kanai and Polack7 in rabbits, which also showed large numbers of lymphocytes in the allograft epithelium. They found macrophages in areas where the epithelial basement membrane was damaged, which is consistent with a macrophage function to phagocytose cell debris rather than as a primary cause of damage. Previous immunohistologic studies of rejection in humans,8 9 sheep,10 rabbits,11 and rats12 13 14 15 16 have concentrated on the stroma, which is easily viewed in sectioned corneas. We found reference to the epithelium only in Larkin et al.,16 who observed mononuclear cells and cells expressing ICAM-1 within the tissue. It is difficult to compare the cell profile we identified in the epithelium with those in the stroma identified by previous investigators, because, even in studies of a single species,12 13 14 15 16 a different combination of antibodies has been used in each study. However, insofar as comparison is possible, it appears that the epithelium contains more T cells than macrophages and granulocytes than does the stroma. Our more recent parallel, unpublished observations (Figueiredo et al., 1998) on stromal cell infiltrates in sectioned tissue in this strain combination, using the same monoclonal antibodies as in this study, confirm this.
Altogether, the data support the notion of differential migration of T cells into the epithelial layer. This would occur initially at the limbus, but as vessels ingress, it may also occur through the corneal stroma. Access to the epithelium may be facilitated at the grafthost junction, where there is more likely to be discontinuity in the epithelial basement membrane. This migration into the epithelium may be mediated by ICAM-1 (CD54) expressed on epithelial cells, through its ligand lymphocyte function-associated antigen (LFA)-1 (CD18/CD11a) on lymphocytes, in a manner similar to the ICAM-1mediated extravasation of lymphocytes across vascular endothelium. This predominance of T cells in the donor epithelium, including in the rejection line, suggests that epithelial rejection may be mediated primarily by T cells, rather than by macrophages. We did not stain for CD25 (interleukin-2 receptor), but have observed such cells similarly concentrated in the epithelium of sectioned corneas (Figueiredo et al., unpublished data, 1998), showing that many of the T cells were activated.
The T-cell response could theoretically be directed either against MHC class I or class IIexpressing cells, because we noted in the current study and have observed in sectioned corneas (Figueiredo et al., unpublished data, 1998) that class II is induced on epithelial cells. However, in the case of a fully mismatched graft, it is difficult to reconcile specific cytotoxicity (by either CD4+ or CD8+ cells) as a major mechanism of rejection with the fact that T cells activated by the indirect route (i.e., through recipient APC and biased toward recognition of non-MHC antigens) play a major, if not a decisive, role in rodent corneal graft rejection.4 17 18 19 20 Such recipient-restricted cells would not be of the correct specificity to recognize either MHC class I or II expressed on graft epithelium. T cells with antigen specificity would have to be primed by direct presentation (i.e., MHC class II presented on donor DCs). Such DCs, although present in the rat cornea, are few.21 It is possible that within the indirectly activated T-cell population there is sufficient cross-reactivity for donor MHC to account for donor recognition. Alternatively, invading T cells kill through some as yet undefined, nonantigen-specific mechanism, a possibility also suggested by Sano et al.19 to explain their finding that clinical rejection of fully allogeneic mouse corneal grafts correlates with indirect activation of CD8+ T cells. However, if this is the case, it is difficult to explain how such precise specificity for the donor epithelium is achieved. The significance of the observed MHC class II expression on epithelium therefore remains uncertain. An alternative possible role for such expression in an established T-cell response and a cytokine-rich environment, may be to specifically upregulate22 23 or downregulate24 CD4+ T cells within the graft, but the same constraints as those just mentioned would applythat is, that only directly activated T cells would be targeted.
Because the patterns of MHC class II and ADPase staining of DCs were very similar, we infer that the ADPase+ cells also express class II and are able to present antigen. The large number of recipient APCs that appeared rapidly in the epithelium is consistent with functional evidence that they play a major role in host sensitization and rejection in rodents.18 19 20 Ross et al.25 previously questioned the importance of recipient APCs in T-cell activation, because an increase in the number of LCs in the donor cornea before transplantation was a major stimulus to rejection. By contrast, rejection was not promoted by natural infiltration of recipient APCs in the early stages after transplantation or the artificial induction of LC infiltration into a nonrejected corneal graft after day 60. However, their model was different from ours in a number of respects. They used an MHC-matched strain combination in which rejection occurred less acutely (in only 26% of cases) and did not compare infiltration in allografts directly with that in isografts. In addition, although in humans1 and rabbits,2 donor epithelium can persist for months if not rejected, in mice it appears to be lost by approximately 2 weeks.26 In the rat it is possible that nonrejected epithelial cells are replaced naturally by recipient cells by day 60. In this case, infiltrating LCs would not encounter the stimulus of alloantigen in the epithelium.
The data provide no direct proof that these recipient APCs migrate to the draining lymph nodes where T-cell activation takes place. However, in allograft donor and recipient epithelium, we noted a difference in the profile of cells of APC phenotype (ADPase+ cells, class II+ cells, and macrophages) compared with effector cells (T cells and neutrophils). Effector cells, although initially more numerous in the recipient, were all considerably more numerous in the donor at maximal rejection on day 15. This is consistent with unidirectional migration and accumulation in the donor to perform their effector functions, eventually dying in situ. By contrast, although their numbers were increasing in the donor up to day 15, all categories of APC were more numerous in the recipient than in the donor until rejection was resolving (i.e., day 30). Although there may be other explanations for this, such a profile would be expected if these cells were trafficking in both directions: into the cornea and out again. Both DCs27 and T cells expressed the costimulatory molecule CD2. It has been shown that cross-linking of CD2 stimulates sessile T cells to migrate.28 Its strong expression is thus consistent with high activation and mobility of both cell types. As well as APC trafficking to the lymph node to prime T cells, others that infiltrate the graft may function to promote the ongoing effector response by actively processing and presenting graft antigens to T cells in situ.29
The gradual clearing of the cornea after rejection can be attributed to the capacity of rat endothelial cells to proliferate.30 As opacity subsided, we noted that ADPase+ cells diminished in number in the donor cornea less rapidly than in the host and less rapidly than T cells, with the result that in ADPase+ cells in the donor cornea exceeded those in the recipient on day 30 (Fig. 3) . Because statistical comparisons could not be made at individual time points, it is impossible to determine whether this difference was significant, but it may represent a reduction in APC trafficking to the lymph node in parallel with clearance of antigen. ADPase+ cells remained in the donor epithelium 100 days after transplantation. Continued secretion of chemotactic factors due to the inflammatory stimulus of sutures may have been a contributory factor.
The relatively large number of epithelial cells in a graft and the accessibility of epithelium to indirect presentation through host APCs are strong a priori reasons to suppose that the epithelium plays an important role in host sensitization. Antigen in human epithelium may also include a few LCs in a fresh central corneal button.31 32 In humans, attempts have been made to address the question of epithelial immunogenicity and to improve graft survival by removal of the epithelium before transplantation, but results have been conflicting. Tuberville et al.33 found that this reduced the number of graft reactions, whereas later studies by Sundmacher34 and Stulting et al.35 did not confirm this finding. Removal of epithelium from corneas transplanted heterotopically into subcutaneous pockets in the mouse prolonged survival,36 whereas replacement of epithelium of an orthotopic corneal allograft with epithelium syngeneic with the recipient significantly prolonged survival, provided that the epithelium was deprived of LCs.37 An interesting finding of Hori and Streilein37 was that allogeneic grafts deprived of epithelium undergo enhanced rejection compared with full-thickness grafts. This was attributed to enhanced inflammation and more intense stromal vascularization in denuded grafts and may explain the poor performance of grafts in humans when deprived of epithelium.34 35 These study results are not inconsistent with an immunogenic role for allogeneic epithelium, but also reveal a conflicting protective effect that is related to an ability to inhibit neovascularization.
A further complicating consideration is the strong non-MHC component of target antigens in corneal graft rejection, which may be cell type specific. However, there is no evidence from the rat that the three layers are separately targeted, because they are rejected more or less simultaneously, with infiltration of the endothelium also reaching maximal levels around day 15 in this strain combination38 (although the infiltration does not begin until day 11 or 12, and isografts are not infiltrated). Data from rabbits, without immunosuppression, suggest that all three layers are likely to be targeted, either simultaneously or in close succession, if, as in these experiments, corneas are vascularized.39 In humans, the effect of immunosuppressants, in combination with the unique layered structure of the cornea wherein the endothelium is more accessible to effector cells from the iris, rather than antigenic differences, may explain why differential rejection so frequently occurs.
The observation of epithelial rejection as long as 13 months after transplantation in humans1 is strong evidence that epithelium is not rapidly replaced by host tissue unless rejected. Because rejected epithelium is rapidly replaced by recipient cells, loss of rejected tissue poses no direct threat to vision. Consequently, the incidence of epithelial rejection is almost certainly underestimated, because symptoms are mild and may be missed between outpatient appointments.1 However, recognition of epithelial rejection can show that the recipient is sensitized and that activated cells are reaching the graft. The fact that, if it does not coincide with endothelial rejection, epithelial rejection always precedes it1 means that, seen alone, it may be a valuable signal of an increased risk of endothelial rejection and a need for closer monitoring of the patient and prolonged prophylactic treatment with topical steroids. Because of this, detection of epithelial rejection should perhaps be given greater clinical priority, especially in patients known to be in a high risk category.
| Acknowledgements |
|---|
| Footnotes |
|---|
Submitted for publication July 17, 2001; revised October 16, 2001; accepted November 2, 2001.
Commercial relationships policy: N.
The publication costs of this article were defrayed in part by page
charge payment. This article must therefore be marked
"advertisement" in accordance with 18 U.S.C.
1734
solely to indicate this fact.
Corresponding author: Susan Nicholls, Division of Ophthalmology, School of Medical Sciences, University Walk, Bristol, BS8 1TD, UK; s.m.nicholls{at}bris.ac.uk
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
S. M. Nicholls and A. D. Dick Lack of IFN-{gamma} Synthesis in Aqueous Humor during Corneal Graft Rejection Correlates with Suppressed Nitric Oxide Production by Macrophages Invest. Ophthalmol. Vis. Sci., November 1, 2008; 49(11): 4923 - 4930. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |